Subtopic Deep Dive
Autoantibodies in Peripheral Neuropathies
Research Guide
What is Autoantibodies in Peripheral Neuropathies?
Autoantibodies in peripheral neuropathies are serum antibodies targeting gangliosides like GQ1b and GM1, or proteins such as contactin and neurofascin, associated with Guillain-Barré syndrome (GBS), Miller Fisher syndrome (MFS), and chronic inflammatory demyelinating polyneuropathy (CIDP) variants.
These autoantibodies disrupt nodal sodium channel clusters and correlate with specific clinical phenotypes including ophthalmoplegia and acute flaccid paralysis (Chiba et al., 1993; Susuki et al., 2007). Over 20 years of research maps their discovery from IgM paraproteinaemic neuropathy to GBS subtypes (Willison, 2002). Key reviews cite 1505 (Willison et al., 2016) and 1021 (van den Berg et al., 2014) citations.
Why It Matters
Detection of anti-GQ1b IgG enables precision diagnosis of MFS and GBS variants with ophthalmoplegia, guiding targeted immunotherapies like plasma exchange (Chiba et al., 1993; Hahn et al., 1996). Anti-GM1 antibodies cause complement-mediated nodal disruption, explaining motor nerve failure in GBS and informing complement inhibitor trials (Susuki et al., 2007; Dalakas et al., 2020). Serological stratification improves treatment response prediction in CIDP, reducing reliance on broad immunosuppressants (Willison et al., 2016).
Key Research Challenges
Antibody Specificity Variability
Anti-glycolipid antibodies show heterogeneous binding affinities across GBS subtypes, complicating diagnostic assays (Willison, 2002). Clinical correlation varies, with anti-GQ1b IgG present in MFS but not all ophthalmoplegia cases (Chiba et al., 1993). Standardization of detection methods remains unresolved (van den Berg et al., 2014).
Pathogenic Mechanism Proof
While anti-GM1 disrupts NaV clusters via complement, causality in human disease requires validation beyond models (Susuki et al., 2007). Molecular mimicry from Campylobacter triggers unclear antibody production pathways (Nachamkin et al., 1998). Therapeutic targeting of complement needs neuropathy-specific trials (Dalakas et al., 2020).
Phenotype-Serology Correlation
Linking specific autoantibodies to treatment responses in CIDP variants is inconsistent across cohorts (Hahn et al., 1996). Epidemiological prevalence data lacks integration with serology for risk stratification (Martyn and Hughes, 1997). Prospective studies on anti-contactin/neurofascin antibodies are limited (Willison et al., 2016).
Essential Papers
Guillain-Barré syndrome
Hugh J. Willison, Bart C. Jacobs, Pieter A. van Doorn · 2016 · The Lancet · 1.5K citations
Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis
Bianca van den Berg, Christa Walgaard, Judith Drenthen et al. · 2014 · Nature Reviews Neurology · 1.0K citations
Peripheral neuropathies and anti-glycolipid antibodies
H J Willison · 2002 · Brain · 710 citations
This review charts the progress of anti-glycolipid antibodies in neuropathy, from their original discovery 20 years ago in immunoglobulin M paraproteinaemic neuropathy through to current discoverie...
Serum anti‐GQ <sub>1b</sub> IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain‐Barre syndrome
Atsuro Chiba, Susumu Kusunoki, Ryo Obata et al. · 1993 · Neurology · 694 citations
To determine the significance of serum anti-GQ1b IgG antibody, we studied the disease spectrum associated with this antibody and GQ1b epitope in the human nervous system. We examined sera from 19 p...
Epidemiology of peripheral neuropathy.
C N Martyn, Richard AC Hughes · 1997 · Journal of Neurology Neurosurgery & Psychiatry · 585 citations
<i>Campylobacter</i>Species and Guillain-Barre Syndrome
Irving Nachamkin, Ban Mishu Allos, Tony W. Ho · 1998 · Clinical Microbiology Reviews · 583 citations
SUMMARY Since the eradication of polio in most parts of the world, Guillain-Barré syndrome (GBS) has become the most common cause of acute flaccid paralysis. GBS is an autoimmune disorder of the p...
Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: A double-blind, sham-controlled, cross-over study
Angelika F. Hahn, C. F. Bolton, Neelan Pillay et al. · 1996 · Brain · 402 citations
Eighteen patients with definite, untreated chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) of chronic progressive (nine patients) or relapsing course (nine patients) were randomize...
Reading Guide
Foundational Papers
Start with Willison (2002, 710 citations) for anti-glycolipid historical mapping; Chiba et al. (1993, 694 citations) for GQ1b discovery in MFS/GBS; van den Berg et al. (2014, 1021 citations) for pathogenesis overview.
Recent Advances
Willison et al. (2016, 1505 citations) updates GBS diagnostics; Susuki et al. (2007, 368 citations) details GM1 nodal disruption; Dalakas et al. (2020, 335 citations) covers complement therapeutics.
Core Methods
Serological assays (ELISA for GQ1b/GM1); complement deposition on nerve models; nodal NaV cluster imaging via immunofluorescence (Chiba et al., 1993; Susuki et al., 2007).
How PapersFlow Helps You Research Autoantibodies in Peripheral Neuropathies
Discover & Search
Research Agent uses searchPapers and exaSearch to find 250M+ papers on anti-GQ1b in MFS, then citationGraph traces from Chiba et al. (1993, 694 citations) to Odaka (2001, 381 citations) and Willison et al. (2016, 1505 citations). findSimilarPapers expands to contactin antibodies in CIDP.
Analyze & Verify
Analysis Agent applies readPaperContent to extract anti-GM1 nodal disruption mechanisms from Susuki et al. (2007), then verifyResponse with CoVe chain-of-verification flags inconsistencies across van den Berg et al. (2014). runPythonAnalysis statistically correlates antibody prevalence with GBS phenotypes using pandas on extracted cohort data; GRADE grading scores evidence as high for GQ1b association.
Synthesize & Write
Synthesis Agent detects gaps in contactin antibody treatment trials via contradiction flagging between Willison (2002) and recent reviews, exporting Mermaid diagrams of antibody-pathway graphs. Writing Agent uses latexEditText, latexSyncCitations, and latexCompile to generate a review manuscript with synchronized bibtex from Willison et al. (2016).
Use Cases
"Run statistical analysis on anti-GQ1b prevalence in GBS cohorts from 1993-2016 papers."
Research Agent → searchPapers('anti-GQ1b GBS') → Analysis Agent → readPaperContent(Chiba 1993 + van den Berg 2014) → runPythonAnalysis(pandas cohort meta-analysis plot) → matplotlib prevalence graph output.
"Draft LaTeX review on anti-GM1 pathogenicity in peripheral neuropathies."
Synthesis Agent → gap detection(Willison 2002 + Susuki 2007) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(10 papers) → latexCompile → PDF manuscript with figures.
"Find code for ganglioside antibody binding simulations from neuropathy papers."
Research Agent → paperExtractUrls(Willison papers) → Code Discovery → paperFindGithubRepo → githubRepoInspect → verified simulation code for anti-GM1 complement models.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ GBS autoantibody papers: searchPapers → citationGraph(Willison hub) → DeepScan(7-step CoVe analysis) → GRADE-graded report on serology-treatment links. Theorizer generates hypotheses on neurofascin antibody evolution from foundational Chiba (1993) to Dalakas (2020). DeepScan verifies Campylobacter mimicry claims across Nachamkin (1998) and van den Berg (2014).
Frequently Asked Questions
What defines autoantibodies in peripheral neuropathies?
Serum IgG/IgM antibodies targeting gangliosides (GQ1b, GM1) or nodal proteins (contactin, neurofascin) in GBS, MFS, and CIDP (Willison, 2002; Chiba et al., 1993).
What are key methods for detection?
ELISA and cell-based assays measure anti-GQ1b/GM1 titers; complement activation tests assess pathogenicity (Chiba et al., 1993; Susuki et al., 2007).
What are seminal papers?
Willison et al. (2016, 1505 citations) reviews GBS; Chiba et al. (1993, 694 citations) links GQ1b to ophthalmoplegia; Willison (2002, 710 citations) maps anti-glycolipid progress.
What open problems exist?
Proving causality of rare antibodies like anti-neurofascin in CIDP; standardizing assays for clinical use; integrating serology into precision therapy trials (Dalakas et al., 2020; Willison et al., 2016).
Research Peripheral Neuropathies and Disorders with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Autoantibodies in Peripheral Neuropathies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers